Literature DB >> 24159166

Anti-hepcidin therapy for iron-restricted anemias.

Elizabeta Nemeth1.   

Abstract

In this issue of Blood, Cooke et al demonstrate the potential of a fully human anti-hepcidin antibody as a novel therapeutic for iron-restricted anemias such as anemia of inflammation, cancer, or chronic kidney disease (formerly known as “anemia of chronic diseases”).

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24159166      PMCID： PMC8940288          DOI： 10.1182/blood-2013-08-522466

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  6 in total

Review 1.  The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

Review 2.  Detection, evaluation, and management of iron-restricted erythropoiesis.

Authors:  Lawrence Tim Goodnough; Elizabeta Nemeth; Tomas Ganz
Journal:  Blood       Date:  2010-09-08       Impact factor: 22.113

Review 3.  Hepcidin and disorders of iron metabolism.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

4.  Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA).

Authors:  Karin E Finberg; Matthew M Heeney; Dean R Campagna; Yeşim Aydinok; Howard A Pearson; Kip R Hartman; Mary M Mayo; Stewart M Samuel; John J Strouse; Kyriacos Markianos; Nancy C Andrews; Mark D Fleming
Journal:  Nat Genet       Date:  2008-04-13       Impact factor: 38.330

Review 5.  A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR).

Authors:  Charles L Bennett; David M Spiegel; Iain C Macdougall; LeAnn Norris; Zaina P Qureshi; Oliver Sartor; Stephen Y Lai; Martin S Tallman; Dennis W Raisch; Sheila Weiss Smith; Samuel Silver; Alanna S Murday; James O Armitage; David Goldsmith
Journal:  Semin Thromb Hemost       Date:  2012-10-30       Impact factor: 4.180

6.  A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates.

Authors:  Keegan S Cooke; Beth Hinkle; Hossein Salimi-Moosavi; Ian Foltz; Chadwick King; Palaniswami Rathanaswami; Aaron Winters; Shirley Steavenson; C Glenn Begley; Graham Molineux; Barbra J Sasu
Journal:  Blood       Date:  2013-08-14       Impact factor: 22.113
  6 in total
  4 in total

Review 1.  Iron Balance and the Role of Hepcidin in Chronic Kidney Disease.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Semin Nephrol       Date:  2016-03       Impact factor: 5.299

Review 2.  Management of the Jehovah's Witness in Obstetrics and Gynecology: A Comprehensive Medical, Ethical, and Legal Approach.

Authors:  Burak Zeybek; Andrew M Childress; Gokhan S Kilic; John Y Phelps; Luis D Pacheco; Michele A Carter; Mostafa A Borahay
Journal:  Obstet Gynecol Surv       Date:  2016-08       Impact factor: 2.347

Review 3.  Anemia in inflammatory bowel disease: an under-estimated problem?

Authors:  Gerhard Rogler; Stephan Vavricka
Journal:  Front Med (Lausanne)       Date:  2015-01-19

4.  Effect of calcitriol on serum hepcidin in individuals with chronic kidney disease: a randomized controlled trial.

Authors:  Bhupesh Panwar; Diane McCann; Gordana Olbina; Mark Westerman; Orlando M Gutiérrez
Journal:  BMC Nephrol       Date:  2018-02-09       Impact factor: 2.388
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.